Tikvah Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.1M | Sell |
68,604
-29,230
| -30% | -$8.29M | 6.12% | 7 |
|
|
2026
Q1 | $27.3M | Sell |
97,834
-13,250
| -12% | -$3.82M | 8.45% | 4 |
|
|
2025
Q4 | $33.7M | Hold |
111,084
| – | – | 8.99% | 4 |
|
|
2025
Q3 | $31.1M | Hold |
111,084
| – | – | 9.2% | 4 |
|
|
2025
Q2 | $26.8M | Hold |
111,084
| – | – | 8.63% | 4 |
|
|
2025
Q1 | $27.1M | Sell |
111,084
-7,063
| -6% | -$2.12M | 9.22% | 3 |
|
|
2024
Q4 | $38.8M | Hold |
118,147
| – | – | 10.57% | 3 |
|
|
2024
Q3 | $39.5M | Hold |
118,147
| – | – | 12.25% | 2 |
|
|
2024
Q2 | $32.3M | Hold |
118,147
| – | – | 10.52% | 3 |
|
|
2024
Q1 | $40.9M | Hold |
118,147
| – | – | 12.8% | 2 |
|
|
2023
Q4 | $38.1M | Hold |
118,147
| – | – | 13.09% | 2 |
|
|
2023
Q3 | $42.3M | Hold |
118,147
| – | – | 15.19% | 2 |
|
|
2023
Q2 | $44.8M | Buy |
118,147
+21,120
| +22% | +$8.59M | 15.23% | 2 |
|
|
2023
Q1 | $46.5M | Hold |
97,027
| – | – | 19.1% | 1 |
|
|
2022
Q4 | $40.8M | Hold |
97,027
| – | – | 19.48% | 1 |
|
|
2022
Q3 | $40.5M | Hold |
97,027
| – | – | 18.71% | 2 |
|
|
2022
Q2 | $48M | Hold |
97,027
| – | – | 20.7% | 1 |
|
|
2022
Q1 | $54.6M | Buy |
+97,027
| New | +$58.5M | 17.47% | 2 |
|
|
2021
Q2 | – | Sell |
-126,282
| Closed | -$72.1M | – | 19 |
|
|
2021
Q1 | $72.1M | Hold |
126,282
| – | – | 20.23% | 1 |
|
|
2020
Q4 | $73.6M | Hold |
126,282
| – | – | 20.52% | 1 |
|
|
2020
Q3 | $65.1M | Sell |
126,282
-11,730
| -8% | -$5.94M | 20.1% | 1 |
|
|
2020
Q2 | $62.3M | Hold |
138,012
| – | – | 19.05% | 2 |
|
|
2020
Q1 | $48.4M | Sell |
138,012
-11,400
| -8% | -$4.19M | 19.15% | 2 |
|
|
2019
Q4 | $55.3M | Hold |
149,412
| – | – | 14.3% | 1 |
|
|
2019
Q3 | $49.7M | Hold |
149,412
| – | – | 13.86% | 1 |
|
|
2019
Q2 | $46.7M | Hold |
149,412
| – | – | 13.25% | 2 |
|
|
2019
Q1 | $45.7M | Buy |
149,412
+5
| +0% | +$1.35K | 15.16% | 2 |
|
|
2018
Q4 | $34.7M | Hold |
149,407
| – | – | 12.31% | 3 |
|
|
2018
Q3 | $46.8M | Hold |
149,407
| – | – | 13.98% | 3 |
|
|
2018
Q2 | $43.1M | Hold |
149,407
| – | – | 13.53% | 3 |
|
|
2018
Q1 | $37.4M | Buy |
149,407
+11,400
| +8% | +$2.9M | 11.48% | 3 |
|
|
2017
Q4 | $32.9M | Hold |
138,007
| – | – | 13.25% | 2 |
|
|
2017
Q3 | $30.7M | Hold |
138,007
| – | – | 13% | 2 |
|
|
2017
Q2 | $31.2M | Hold |
138,007
| – | – | 14.7% | 2 |
|
|
2017
Q1 | $27.5M | Hold |
138,007
| – | – | 14.43% | 1 |
|
|
2016
Q4 | $25.2M | Hold |
138,007
| – | – | 12.36% | 2 |
|
|
2016
Q3 | $22.6M | Hold |
138,007
| – | – | 11.8% | 2 |
|
|
2016
Q2 | $19.7M | Hold |
138,007
| – | – | 11.55% | 3 |
|
|
2016
Q1 | $18.9M | Hold |
138,007
| – | – | 10.49% | 4 |
|
|
2015
Q4 | $19.1M | Buy |
138,007
+28,900
| +26% | +$4.01M | 10.03% | 4 |
|
|
2015
Q3 | $14.7M | Hold |
109,107
| – | – | 8.16% | 4 |
|
|
2015
Q2 | $16.4M | Buy |
109,107
+13,910
| +15% | +$1.99M | 8.72% | 4 |
|
|
2015
Q1 | $12.9M | Hold |
95,197
| – | – | 7.1% | 6 |
|
|
2014
Q4 | $11.5M | Buy |
+95,197
| New | +$11M | 7.49% | 5 |
|
|
2014
Q2 | – | Sell |
-95,197
| Closed | -$12.2M | – | 17 |
|
|
2014
Q1 | $12.2M | Buy |
+95,197
| New | +$12.2M | 9.02% | 3 |
|
Other funds holding BIO
AI
Tikvah Management's BIO Position: Q2 2026 in Review
Tikvah Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 30% in Q2 2026, selling an estimated $8.29M and leaving 68,604 shares worth $20.1M. The position accounts for 6.12% of the portfolio, ranked #7.
Tikvah Management first reported a position in BIO in Q1 2014 and has held it in 45 quarters since. The position peaked at $73.6M in Q4 2020. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Tikvah Management held 68,604 shares of Bio-Rad Laboratories Class A worth $20.1M as of Q2 2026.
- Tikvah Management sold 29,230 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $8.29M.
- Bio-Rad Laboratories Class A made up 6.12% of Tikvah Management's portfolio in Q2 2026, its #7 holding.
- Tikvah Management first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and has held it in 45 quarters since.
- Tikvah Management's Bio-Rad Laboratories Class A position peaked at $73.6M in Q4 2020.
- 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Tikvah Management's 13F filing for Q2 2026, filed 13 Aug 2026.